Unicycive Therapeutics (NASDAQ:UNCY) Stock Moved Up to Hold by Wall Street Zen

Unicycive Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Wall Street Zen upgraded Unicycive Therapeutics from “sell” to “hold.” Overall analyst sentiment remains “Moderate Buy,” with a consensus price target of $18.25.
  • The stock was down 5.1%, opening at $3.35—near its 52-week low of $3.33. Its 50-day and 200-day moving averages were $4.03 and $5.86, respectively.
  • Unicycive reported a quarterly loss of $0.25 per share, narrower than analysts’ expected loss of $0.35 per share. Analysts expect a full-year loss of $1.05 per share.
  • MarketBeat previews the top five stocks to own by December 1st.

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "sell" rating to a "hold" rating in a report issued on Sunday, Wall Street Zen reports.

Several other research firms have also recently commented on UNCY. HC Wainwright cut their price target on Unicycive Therapeutics from $15.00 to $13.00 and set a "buy" rating for the company in a research note on Tuesday, September 29th. Benchmark reiterated a "speculative buy" rating and issued a $15.00 price objective (up from $13.00) on shares of Unicycive Therapeutics in a research report on Thursday, August 20th. Zacks Research raised shares of Unicycive Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Wednesday, August 19th. B. Riley Financial restated a "buy" rating and issued a $20.00 target price (down from $22.00) on shares of Unicycive Therapeutics in a research note on Wednesday, August 12th. Finally, Guggenheim restated a "buy" rating and issued a $25.00 target price (down from $37.00) on shares of Unicycive Therapeutics in a research note on Thursday, August 13th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Unicycive Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $18.25.

View Our Latest Research Report on Unicycive Therapeutics

Unicycive Therapeutics Stock Down 5.1%

NASDAQ UNCY opened at $3.35 on Friday. Unicycive Therapeutics has a 52-week low of $3.33 and a 52-week high of $8.74. The business's 50-day moving average price is $4.03 and its 200 day moving average price is $5.86. The firm has a market cap of $97.75 million, a P/E ratio of -2.01 and a beta of 1.91.

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) last posted its quarterly earnings data on Monday, November 16th. The company reported ($0.25) earnings per share for the quarter, topping analysts' consensus estimates of ($0.35) by $0.10. As a group, analysts anticipate that Unicycive Therapeutics will post -1.05 earnings per share for the current year.

Hedge Funds Weigh In On Unicycive Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Dimensional Fund Advisors LP acquired a new position in Unicycive Therapeutics in the first quarter valued at approximately $940,000. Goldman Sachs Group Inc. raised its position in shares of Unicycive Therapeutics by 80.8% during the 3rd quarter. Goldman Sachs Group Inc. now owns 262,767 shares of the company's stock worth $1,234,000 after purchasing an additional 117,463 shares during the period. Seven Fleet Capital Management LP acquired a new stake in shares of Unicycive Therapeutics during the 1st quarter worth approximately $367,000. Bank of New York Mellon Corp acquired a new stake in shares of Unicycive Therapeutics during the 2nd quarter worth approximately $248,000. Finally, Virtu Financial LLC lifted its holdings in shares of Unicycive Therapeutics by 412.4% in the 3rd quarter. Virtu Financial LLC now owns 59,484 shares of the company's stock worth $279,000 after purchasing an additional 47,874 shares during the last quarter. 40.42% of the stock is owned by institutional investors and hedge funds.

Latest Unicycive Therapeutics News

Here's some of the latest news about UNCY:

  • Positive Sentiment: HC Wainwright raised several 2026–27 EPS estimates, kept its Buy rating, and reiterated a $13 price target—potential support for the stock. HC Wainwright forecast article
  • Negative Sentiment: A report said Unicycive’s third-quarter loss widened to $7.0 million, highlighting ongoing losses. Article on Unicycive’s Q3 loss
  • Negative Sentiment: Despite raising near-term estimates, HC Wainwright cut its 2028–30 EPS forecasts substantially. Noble Financial also lowered its 2026 estimates, adding a more cautious note to the outlook. Analyst estimate reports

Unicycive Therapeutics Company Profile

(Get Free Report)

Unicycive Therapeutics is a biopharmaceutical company focused on developing treatments for kidney diseases. Its lead program, oxylanthanum carbonate (OLC), is an oral phosphate binder being developed to help manage hyperphosphatemia, or elevated blood phosphate levels, in people with chronic kidney disease, including patients receiving dialysis. The company is also developing UNI-494, an investigational small-molecule therapy for acute kidney injury. These programs reflect Unicycive's focus on conditions for which treatment options may be limited.

Further Reading

Analyst Recommendations for Unicycive Therapeutics (NASDAQ:UNCY)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Unicycive Therapeutics Right Now?

Before you consider Unicycive Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Unicycive Therapeutics wasn't on the list.

While Unicycive Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines